The Latest Breaking News from Novo Nordisk

How Investors are Capitalizing on the Ozempic and Wegovy Craze

Ozempic and Wegovy started as injectable diabetes treatments. But now, these “appetite suppressants” are being touted as miracle weight loss drugs.

Barchart · Mar 29, 2023

Stay Forever Young With These 3 Pharmaceutical Stocks

Despite macroeconomic headwinds, the pharmaceutical industry is anticipated to stay buoyed in the foreseeable future, owing to rising healthcare spending. Against this backdrop, we think the strong fundamentals of Novo Nordisk (NVO), Bristol-Myers Squibb (BMY), and Takeda Pharmaceutical (TAK) make them wise portfolio additions. Read on….

StockNews.com · Mar 29, 2023

WHO to consider adding obesity drugs to ‘essential’ medicines list

A panel of advisers to the WHO will review requests for drugs to be included next month

Evening Standard · Mar 29, 2023

The biggest U.S. pharmaceutical companies are lowering insulin costs to save themselves money

So much for altruism.

Axios · Mar 17, 2023

Anti-obesity drug demand expected to skyrocket, but will insurance cover the cost?

New weight loss drugs can cost more than $1,000 a month, but most health plans don’t cover them.

Chicago Sun-Times · Mar 16, 2023

Firm behind Wegovy slimming jab suspended from UK trade association

Novo Nordisk found to be in breach of ABPI code of practice over sponsored weight-loss courses that promoted its medicines

The Guardian - UK · Mar 16, 2023

Biden drawing contrast to Republicans on lower drug costs

President Joe Biden will highlight the stark differences in how Democrats are tackling skyrocketing drug prices compared to their Republican counterparts as he gears up for an expected reelection announcement

The Independent UK · Mar 15, 2023

Novo Nordisk will cut some U.S. insulin prices by up to 75% starting next year

The Danish drugmaker's move follows a similar announcement by rival Eli Lilly earlier this month. More than 8 million Americans use insulin, according to the American Diabetes Association.

WEKU · Mar 14, 2023

Novo Nordisk to slash insulin price by up to 75% in push for affordable diabetes treatments

The brand is the latest to plan dramatic price cuts for the diabetes drug

The Independent UK · Mar 14, 2023

Why does insulin cost so much? Big Pharma isn’t the only player driving prices

Eli Lilly & Co.’s announcement that it is slashing prices for its major insulin products could make life easier for some diabetes patients while easing pressure on Big Pharma.

Tribune News Service · Mar 14, 2023